Clinical trial: A multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-β-1a in moderately active ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 6, 2008, Pages 758-767

  Pena Rossi, C ^a   Schreiber, S ^b   Golubovic, G ^c   Mertz Nielsen, A ^d   Panes, J ^e   Rachmilewitz, D ^f   Shieh, M J ^g   Simanenkov, V I ^h   Stanton, D ⁱ   Graffner, H ^a  

^a MERCK SERONO S A   (Switzerland)

^b UNIVERSITY OF KIEL   (Germany)

^c Clinical Hospital Center Zemun   (Serbia)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e HOSPITAL CLÍNIC   (Spain)

^f SHAARE ZEDEK MEDICAL CENTER   (Israel)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h St Petersburg City Hospital 2   (Russian Federation)

ⁱ St Petersburg General Clinical Hospital ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; MESALAZINE; PLACEBO;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROATIA; CYTOPENIA; DISEASE DURATION; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOSCOPY; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATOBILIARY DISEASE; HUMAN; HYPOKALEMIA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALAISE; MALE; MENTAL DISEASE; MULTICENTER STUDY; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RUSSIAN FEDERATION; SIDE EFFECT; SMOKING; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; THYROID DISEASE; ULCERATIVE COLITIS; WESTERN EUROPE;

ADULT; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOXICITY; ENDOSCOPY, GASTROINTESTINAL; EUROPE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; PLACEBOS; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 49849103846     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03778.x     Document Type: Article

References (40)

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004 126 : 1504 17.
2. Schreiber S, Rosentiel P, Albrecht M, Hampe J, Krawczak M. Genetics of Crohn's disease, an archetypal inflammatory barrier disease. Nat Rev Genet 2005 6 : 376 88.
3. Lukas M, Bortlik M, Maratka Z. What is the origin of ulcerative colitis? Still more questions than answers. Postgrad Med J 2006 82 : 620 5.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353 : 2462 76.
5. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 1995 101 : 428 35.
6. Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995 154 : 2434 40.
7. Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 1998 42 : 470 6.
8. Seegert D, Rosenstiel P, Pfahler H, Pfefferkorn P, Nikolaus S, Schreiber S. Increased expression of IL-16 in inflammatory bowel disease. Gut 2001 48 : 326 32.
9. Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol 2007 47 : 930 41.
10. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993 94 : 174 81.
11. Keshavarzian A, Fusunyan RD, Jacyno M, Winship D, MacDermott RP, Sanderson IR. Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon. Am J Gastroenterol 1999 94 : 704 12.
12. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1 beta in relapse of Crohn's disease. Lancet 1999 353 : 459 61.
13. Revel M, Chebath J, Mangelus M, Harroch S, Moviglia GA. Antagonism of interferon beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Mult Scler 1995 1 (Suppl. 1 S5 11.
14. Panitch HSFJ, Jonhson K. Recombinant beta interferon inhibits gamma interferon production in multiple sclerosis. Neurology 1989 39 : 171.
15. Lee YJ, Benveniste EN. Stat1 alpha expression is involved in IFN-gamma induction of the class II transactivator and class II MHC genes. J Immunol 1996 157 : 1559 68.
16. Darnell JE Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994 264 : 1415 21.
17. Satoh J, Paty DW, Kim SU. Differential effects of beta and gamma interferons on expression of major histocompatibility complex antigens and intercellular adhesion molecule-1 in cultured fetal human astrocytes. Neurology 1995 45 : 367 73.
18. Devajyothi C, Kalvakolanu I, Babcock GT, Vasavada HA, Howe PH, Ransohoff RM. Inhibition of interferon-gamma-induced major histocompatibility complex class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocytoma cells. Definition of cis-element. J Biol Chem 1993 268 : 18794 800.
19. Brod SA, Marshall GD Jr., Henninger EM, Sriram S, Khan M, Wolinsky JS. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 1996 46 : 1633 8.
20. Rudick RA, Ransohoff RM, Peppler R, VanderBrug Medendorp S, Lehmann P, Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996 40 : 618 27.
21. Schnaper HW, Aune TM, Pierce CW. Suppressor T-cell activation by human leukocyte interferon. J Immunol 1983 131 : 2301 6.
22. Aune TM, Pierce CW. Activation of a suppressor T-cell pathway by interferon. Proc Natl Acad Sci U S A 1982 79 : 3808 12.
23. Saksela E, Timonen T, Cantell K. Human natural killer cell activity is augmented by interferon via recruitment of 'pre-NK' cells. Scand J Immunol 1979 10 : 257 66.
24. Rosenstiel P, Fantini M, Brautigam K, et al. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003 124 : 1001 9.
25. Nikolaus S, Rutgeerts P, Fedorak R, et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 2003 52 : 1286 90.
26. Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment Pharmacol Ther 2002 16 : 1233 9.
27. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987 317 : 1625 9.
28. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994 106 : 287 96.
29. Irvine EJ, Zhou Q, Thompson AK. The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996 91 : 1571 8.
30. Han SW, Gregory W, Nylander D, et al. The SIBDQ: further validation in ulcerative colitis patients. Am J Gastroenterol 2000 95 : 145 51.
31. Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999 28 : S23 7.
32. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007 132 : 763 86.
33. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol 1986 119 : 558 73.
34. Ilnyckyj A, Shanahan F, Anton PA, Cheang M, Bernstein CN. Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997 112 : 1854 8.
35. Van Assche G, Sandborn WJ, Feagan BG, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006 55 : 1568 74.
36. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005 352 : 2499 507.
37. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001 56 : 1628 36.
38. Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005 239 : 67 74.
39. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002 59 : 1496 506.
40. Francis G. Benefit-risk assessment of interferon-beta therapy for relapsing multiple sclerosis. Expert Opin Drug Saf 2004 3 : 289 303.